Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569212 · ClinicalTrials.gov registry record · Phase 4
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
A Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage, sponsored by Madeleine Puissant.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06569212: Recruiting Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage, sponsored by Madeleine Puissant.
NCT06569212 is a Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage that is actively recruiting participants, run by Madeleine Puissant. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569212, a Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage, is actively recruiting participants, sponsored by Madeleine Puissant.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
Primary Outcome
Change (Delta) QTc length between intervention and control groups.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metoprolol
Study Locations (1)
Maine
- MaineHealth - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2029-09 |
| Phase | Phase 4 |
What NCT06569212 shows while recruiting
NCT06569212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Non-Traumatic Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06569212 reports a single indexed study location in Maine.
Frequently Asked Questions
What is clinical trial NCT06569212 about?
NCT06569212 is a clinical study titled "Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)". To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
What is the current status of trial NCT06569212?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-09-23. Estimated completion is 2029-09.
What conditions does trial NCT06569212 study?
This clinical trial studies the following conditions: Non-Traumatic Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT06569212?
The interventions under investigation include: Placebo (DRUG), Metoprolol (DRUG).
Who is sponsoring clinical trial NCT06569212?
This trial is sponsored by Madeleine Puissant, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569212 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06569212's enrollment target sits among peer trials
20 1753rd of 2000 higher than 168 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI